Sk Biopharmaceuticals Co Ltd (326030) — Capital Reinvestment Ratio
Sk Biopharmaceuticals Co Ltd (326030) has a Capital Reinvestment Ratio of 0.16x as of March 2026, meaning it reinvests 0% of its operating cash flow (₩17.92 Billion) in capital expenditures (₩2.94 Billion). Check 326030 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sk Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2025)
This chart tracks Sk Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see 326030 operating cash flow.
Annual Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd (2024–2025)
Year-by-year Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd from 2024 to 2025. See Sk Biopharmaceuticals Co Ltd (326030) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | ₩176.33 Billion | ₩29.51 Billion | ▲ +18.3% |
| 2024 | 0.14x | ₩94.90 Billion | ₩13.42 Billion | — |